Monte Rosa Therapeutics Q3 EPS $0.03 Beats $(0.29) Estimate, Sales $54.366M Beat $29.750M Estimate
Benzinga Newsdesk 1 day ago
NewsEarningsEarnings Beats
Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.29) by 110.34 percent. This is a 109.09 percent increase over losses of $(0.33) per
Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.29) by 110.34 percent. This is a 109.09 percent increase over losses of $(0.33) per share from the same period last year. The company reported quarterly sales of $54.366 million which beat the analyst consensus estimate of $29.750 million by 82.74 percent. This is a 325.80 percent increase over sales of $12.768 million the same period last year.